Chen, X., Wang, W., Zou, Q., Li, J., Hu, C., Hu, C., Lin, Q., Zhu, X., Jiang, Y., Sun, Y., Shen, L., Wang, L., Zou, G., Lin, X., Wang, Y., Lin, S., Li, M., Ao, R., Xu, R., Lin, H., Wang, R., Yang, J., Song, W., Wang, M., Li, B., & Xia, Y. (n.d.). 804 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy. Journal for immunotherapy of cancer, 8, A481. http://access.bl.uk/ark:/81055/vdc_100144726490.0x000007